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Abstract 30 
Background: Bone fractures may have an impact on prognosis of breast cancer. The long-31 
term risk of bone fracture in breast cancer patients have not been thoroughly studied.  32 
Methods: Poisson regression was used to investigate the incidence of hospitalization due to 33 
bone fracture comparing women with and without breast cancer based on Swedish National 34 
registers. Cox regression was used to investigate the risk of being hospitalized with bone 35 
fracture, and subsequent risk of death, in a regional cohort of breast cancer patients.  36 
Results: For breast cancer patients, the five-year risk of bone fracture hospitalization was 37 
4.8% and the 30-day risk of death following a bone fracture hospitalisation was 2.0%. 38 
Compared with general population, breast cancer patients had incidence rate ratios of 1.25 39 
(95% CI: 1.23, 1.28) and 1.18 (95% CI: 1.14, 1.22) for hospitalization due to any bone 40 
fracture and hip fracture respectively. These ratios remained significantly increased for ten 41 
years. Comorbidities (Charlson comorbity index≥1) were associated with the risk of being 42 
hospitalized with bone fracture. Women taking aromatase inhibitors were at increased risk as 43 
compared with women taking tamoxifen (HR=1.48; 95% CI: 0.98-2.22). Breast cancer 44 
patients hospitalized for a bone fracture showed a higher risk of death (HR=1.83; 95% CI: 45 
1.50, 2.22), compared to those without bone fracture.  46 
Conclusions: Women with a previous breast cancer diagnosis are at increased risk of 47 
hospitalization due to a bone fracture, particularly if they have other comorbidities. 48 
 49 
Key words: breast cancer, bone fracture, hospitalization, comorbidity, survival, death   50 
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Introduction 51 
The improved survival over the last few decades has increased awareness about other health 52 
outcomes in women diagnosed with breast cancer. Bone fractures, in particular hip fractures, 53 
have a potential impact on morbidity, quality of life and prognosis of breast cancer patients. 54 
To study risk of bone fracture after a breast cancer diagnosis is of particular clinical relevance 55 
given that osteoporosis is common in postmenopausal women (Bliuc 2009).  56 
Breast cancer treatment influences risk of bone fracture through different mechanisms. 57 
Adjuvant treatment in particular may affect calcium and bone metabolism possibly leading to 58 
an increased risk (Becker 2012). Hormonal therapy with aromatase inhibitors has in fact been 59 
found to be associated with risk of bone fracture in contrast to tamoxifen that has shown a 60 
protective effect (Breast Cancer Trials Committee 1987, Fisher 1989, Rutqvist 2007, Cooke 61 
2008, Amir 2011, Edwards 2011).  Other types of oncologic adjuvant treatment may also 62 
have potential negative effects on the skeleton independent of sex hormones (Pfeilschifter 63 
2000, Arnold 2013). Additionally, increasing evidence is suggesting that bone marrow 64 
microenvironment is involved in the metastatic process (Semesiuk 2013, Benoy 2006). 65 
Finally, it was shown that bone-targeted drugs, like bisphosphonates, may reduce skeletal 66 
metastasis and improve survival (Coleman 2014, Wong 2012). For all these reasons, 67 
bisphosphonates are currently administered to some patients in parallel to the adjuvant 68 
treatment in order to reduce the risk of bone metastasis and to strengthen the bone tissue 69 
(Rizzoli 2012, Van Poznak 2011). 70 
An increased risk of bone fractures in women diagnosed with breast cancer has been shown 71 
but the duration and the magnitude of this risk have not been clarified (Peppone 2014). It is 72 
also not clear whether there is an increased risk of fractures among women with breast cancer 73 
independent of treatment and whether tumor characteristics and comorbidities influence the 74 
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risk. It is also of outmost clinical importance to assess the risk of dying after being 75 
hospitalized with bone fracture in women with a previous breast cancer diagnosis.  76 
The aim of this study is to investigate, in women with a breast cancer diagnosis, the risk of 77 
being hospitalized with a bone fracture and possible effects of patient and tumor 78 
characteristics at breast cancer diagnosis as well as treatment. In addition, we study the risk 79 
of dying following a hospitalization due to a bone fracture.  80 
 81 
Materials and Methods 82 
Study cohorts 83 
Two different cohorts of Swedish women were used to address the research questions. 84 
The first, national cohort, comprised data extracted from a national database. Individuals 85 
from the Swedish Total Population Register were linked by personal identification numbers 86 
to the National Cancer Register (Mattsson 1984, Barlow 2009), the National Cause of Death 87 
Register (Rutqvist 1985), and the Inpatient Register (Ludvigsson 2011). The National Cancer 88 
Register reports all records for each cancer diagnosis made in Sweden coded through the 7th 89 
version of International Classification of Diseases (ICD-7) since 1958. The National Cause of 90 
Death Register collects all causes of death in Sweden that are mandatorily reported since 91 
1952. The Inpatient Register reports hospitalizations in all Sweden since 1987, coded through 92 
the 9th and 10th versions of International Classification of Diseases (ICD-9 and ICD-10), and 93 
has nationwide coverage. This national cohort was restricted to women aged 45 years and 94 
over for the calendar period 1990-2010.  95 
The second, regional cohort, included data extracted from the Stockholm Breast Cancer 96 
Register, a population-based register comprising all women diagnosed with invasive breast 97 
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cancer in the Swedish counties of Stockholm and Gotland from 1976, linked to other national 98 
registers as described for the first cohort. The register has about 99% completeness for 99 
women aged less than 75 years at diagnosis and provides good information about tumor 100 
characteristics at breast cancer diagnosis and treatment (Mattsson 1985). From this register 101 
we extracted all women with a first invasive breast cancer diagnosis in the period 1990-2006 102 
and less than 75 years at diagnosis. Of the n=14,188 remaining observations we further 103 
excluded women with stage IV disease (n=264), with tumors smaller than 1 mm (n=52), who 104 
received neoadjuvant treatment (n=802), and who did not receive any breast cancer surgery 105 
(n=220). A total of n=12,850 women were left for the analysis. We also retrieved information 106 
on comorbid conditions prior to diagnosis through the Inpatient Register and summarized this 107 
into the Charlson Comorbidity Index (CCI) score, a widely used methodology for grouping 108 
comorbid conditions (Quan 2005, Charlson 1987). 109 
In an additional linkage based on the same registries as the regional cohort, women diagnosed 110 
with breast cancer between 2005 and 2008, were further linked to the Swedish Prescribed 111 
Drug Register in order to investigate the potential effect of type of adjuvant hormone 112 
treatment on future fractures. The Swedish Prescribed Drug Register contains information on 113 
all prescribed medicines dispensed by Swedish pharmacies since July 1, 2005, including 114 
dates of prescription and dispense, number of defined daily doses, and classification of drugs 115 
according to the Anatomical Therapeutic Chemical (ATC) Classification System. This 116 
register is reported to be nationwide complete, with <0.3% of data entries with missing 117 
Personal Identification Numbers (Wettermark 2007). Through this linkage, we identified 118 
2551 patients diagnosed with breast cancer between 2005 and 2008 who initiated adjuvant 119 
hormone therapy with at least one prescription of tamoxifen (ATC codes L02BA01) or 120 
aromatase inhibitors (ATC codes L02BG) and were followed until end of 2012. 121 
ICD codes and Events 122 
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Breast cancer diagnoses were based on ICD-7 code 170. The hospitalization events were 123 
defined as: hospitalization after breast cancer diagnosis due to bone fracture, excluding 124 
fractures of the skull and of the neck (ICD-9 codes 805-829, 733.0, 733.93-98 and ICD-10 125 
codes S22, S32, S42, S52, S62, S72, S82, S92, T02, T08, T10, T12, T14.2, M80); and 126 
hospitalization after breast cancer diagnosis due to hip fracture (ICD-9 codes 820, and ICD-127 
10 codes S72.0, S72.1, S72.2). All hospitalization events were defined based on the main 128 
diagnosis of hospitalization. The death events were categorized using the underlying cause of 129 
death.  130 
Ethics 131 
The study was entirely based on data from Swedish health and population registers and was 132 
approved by the Ethical Review Board at Karolinska Institutet, Stockholm, Sweden (Dnr 133 
2011/1898 32; Dnr 2007/821-31/3; Dnr 2012/217-32/2; Dnr 2014/1401-32). No contact was 134 
made with the study participants, data were analyzed anonymously and thus informed 135 
consent was not obtained. This exception from informed consent was confirmed by the 136 
ethical committee. 137 
Statistical analysis 138 
In the national cohort, we first compared the incidence of first recorded bone fracture-related 139 
hospitalizations in women with breast cancer with that in the general female population 140 
resident in Sweden between 1990 and 2010. For women with breast cancer not previously 141 
hospitalized for fracture, the person-time was split by attained age, attained calendar period 142 
and time since cancer diagnosis. For women without breast cancer not previously 143 
hospitalized for fracture, the person-time was split by attained age and attained calendar 144 
period. The follow-up time was calculated as the date of first recorded fracture (for an event), 145 
death, emigration or 31 December 2010, whichever came first. The cohort was analysed 146 
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using Poisson regression, modelling the hospitalization rate using attained age, attained 147 
calendar period and interaction between breast cancer status and time since breast cancer 148 
diagnosis. For flexible model specification, we used generalized additive models with thin 149 
plate splines for the smoothers. We adjusted for a two-dimensional thin plate spline for 150 
attained age and attained calendar period. To calculate the absolute risks in breast cancer 151 
patients, the one- and five-year risks of bone fracture hospitalization were calculated for 152 
cancer diagnoses during 2005-2010, and the 30-day and one-year risk of death following a 153 
bone fracture hospitalisation were calculated for hospitalisations during 2005-2010. For 154 
women from the national population excluding the breast cancer patients, the incidence were 155 
age-standardised to the person-time distribution for the breast cancer patients, and the 156 
mortality rates were age-standardised to the person-time distribution for the breast cancer 157 
patients hospitalised for a bone fracture. The data extraction was performed with SAS 9.4; the 158 
generalized additive models used mgcv package (version 1.7) in R 3.0.   159 
In the regional cohort comprising only women with a previous breast cancer diagnosis, 160 
follow-up started at date of breast cancer diagnosis and was continued until date of first 161 
fracture event, death, first distant metastasis or 31 December 2006, whichever came first. 162 
Hazard ratios (HR) of fracture rates (or death rates depending on the analysis) were estimated 163 
using Cox regression with time since diagnosis as the underlying time scale. The proportional 164 
hazard assumption was tested using the Therneau and Grambsch test. Test for interaction 165 
between age and Charlson comorbidity index was carried out using likelihood ratio test. We 166 
also looked at the risk of dying after hospitalization due to a bone fracture considering three 167 
outcomes: death due to any cause, death due to breast cancer and death due to causes other 168 
than breast cancer. In the analysis of the risk of dying after being hospitalised for a fracture, 169 
person-time was divided by time before and after first recorded hospitalization due to a 170 
fracture. When looking at cause-specific death we also censored the analysis for the other 171 
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causes of death. The analysis of the regional cohort was performed using the statistical 172 
software package STATA 12.1. All tests were two-sided and the level of significance was 173 
5%. 174 
 175 
Results 176 
Of all 10,866 hospitalizations due to bone fractures in the Swedish national cohort of women 177 
diagnosed with breast cancer between 1990 and 2010 and aged less than 75 years at 178 
diagnosis, 4,008 (36.9%) were hip fractures.  Hip fractures increased over age and 179 
consequently over time since diagnosis, while other lower limb fractures decreased, and 180 
upper limb fractures remained stable (Supplementary Table 1). In total, 3,895 (35.8%) 181 
hospitalizations due to bone fractures occurred within 5 years since breast cancer diagnosis. 182 
Most hospitalizations due to bone fractures occurred in women aged 61-74 years at breast 183 
cancer diagnosis (n=7,364, 67.8%). For the breast cancer patients diagnosed during 2005-184 
2010, the one-year risk of bone fracture was 0.94% (95% CI: 0.83-1.05) and the five-year 185 
risk was 4.82% (95% CI: 4.55-5.06). For the population excluding the breast cancer patients 186 
during 2005-2010, the standardised one-year risk was 0.812% (95% CI: 0.806-0.817) and the 187 
standardised five-year risk was 3.97% (95% CI: 3.94-3.99). When looking at risk of death 188 
after bone fracture hospitalization, for breast cancer patients with a bone fracture 189 
hospitalisation during 2005-2010, the 30-day risk of death was 1.95% (95% CI: 1.72-2.18) 190 
and the one-year risk of death was 18.4% (95% CI: 17.2-19.5). For the population without 191 
breast cancer patients with a bone fracture hospitalisation, the standardised 30-day risk of 192 
death was 1.43% (95% CI: 1.41-1.46) and the standardised one-year risk of death was 16.1% 193 
(95% CI: 15.8-16.3). 194 
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The overall rate ratios for hospitalization due to any bone fracture and for hospitalization due 195 
to hip fracture comparing breast cancer patients with the general population was 1.25 (95% 196 
CI: 1.23-1.28) and 1.18 (95% CI: 1.14-1.22) respectively, after adjusting for attained age and 197 
calendar period. These rate ratios gradually decreased over time, but remained significantly 198 
increased for 10 years since breast cancer diagnosis (Figure 1). The rate ratio of 199 
hospitalization due to any bone fracture after breast cancer was significantly increased in all 200 
ages and decreased with increasing age, from about 1.70 at the attained age of 40 years to 201 
about 1.20 at the age of 80 years. The rate ratio of hospitalization due to a hip fracture was 202 
also significantly increased in women of all ages, ranging from above 3.00 at the attained age 203 
of 40 years to about 1.20 at the age of 80 years. 204 
Table 1 shows, in the regional cohort of women with breast cancer, the frequency distribution 205 
of breast cancer patients (n=12,850) with hospitalizations due to any bone fracture (n=600) 206 
and with hospitalizations due to hip fracture (n=209) after breast cancer diagnosis, across 207 
different characteristics. Hospitalizations due to bone fracture after breast cancer occurred 208 
more often in patients 61-74 years of age at breast cancer diagnosis (64.0% for any bone 209 
fracture, 79.4% for hip fracture). Of the total n=12,850 breast cancer patients included in the 210 
analysis, n=1,534 (12%) developed a first distant metastasis during the study period (mean 211 
follow-up time=5.8 years). All 1,534 (100%) had available information on date of first distant 212 
metastasis. 213 
Table 2 shows the adjusted HRs of hospitalizations due to bone fracture after breast cancer 214 
diagnosis, comparing different subgroups of breast cancer patients from the regional cohort 215 
of breast cancer patients. After testing for proportional hazards, we could not find any 216 
evidence of time-dependent effects, therefore only a proportional hazards analysis was 217 
performed. The HR for being hospitalized with any bone fracture or with hip fracture for 218 
women ≤50 years at breast cancer diagnosis was 0.28 (95% CI: 0.20-0.38) and 0.10 (95% CI: 219 
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0.05-0.22) respectively, as compared with women 61-74 years at breast cancer diagnosis. 220 
Calendar period at breast cancer diagnosis, tumor characteristics and adjuvant treatment 221 
combinations were not significantly associated with the risk of hospitalization due to bone 222 
fracture. Charlson comorbidity index scoring as low as one was significantly associated with 223 
the risk of hospitalization due to any bone fracture (HR=1.63; 95%CI: 1.29-2.06) or due to 224 
hip fracture alone (HR=2.31; 95%CI: 1.61-3.32).  225 
We also performed an additional analysis using a regional cohort of women with information 226 
on drug use based on The Swedish Prescribed Drug Register (Figure 3). The 5-year 227 
cumulative incidence of bone fracture for those patients treated with tamoxifen, aromatase 228 
inhibitors, or chemotherapy without hormone therapy were 3.0% (95% CI: 2.3%-4.0%), 5.9% 229 
(95% CI: 4.6%-7.6%), and 4.1% (95% CI: 2.5%-6.7%), respectively. As compared with the 230 
general population, the corresponding standardized incidence ratios for bone fractures were 231 
0.94 (95% CI: 0.60-1.45), 1.32 (95% CI: 0.89-1.96), and 1.39 (95% CI: 0.66-2.91), 232 
respectively. Furthermore, we found that women taking aromatase inhibitors were at higher 233 
risk of being hospitalized with a bone fracture as compared with women taking tamoxifen 234 
(HR=1.52; 95% CI: 1.03-2.22) in postmenopausal women. Similar results were found when 235 
further adjusting for age, tumor size and lymph node status (HR=1.48; 95% CI: 0.98-2.22).  236 
Table 3 shows the risk of dying comparing women with or without a bone fracture in the 237 
regional cohort of breast cancer patients. After being hospitalized with a bone fracture the HR 238 
of dying due to any cause was 1.83 (95% CI: 1.50-2.22) as compared with not being 239 
hospitalized with a bone fracture. This HR was most pronounced among women 61-74 years 240 
at breast cancer diagnosis (HR=2.16; 95% CI: 1.70-2.75) while it was not significant in 241 
women younger than 61 years at breast cancer diagnosis.   242 
 243 
12 
 
Discussion 244 
Our major findings are that breast cancer patients were at increased risk of being hospitalized 245 
with a bone fracture for at least 10 years since breast cancer diagnosis, that the presence of at 246 
least one comorbidity was associated with an increased risk of being hospitalized with a bone 247 
fracture, that patients using aromatase inhibitors were at higher risk of having a fracture 248 
compared to tamoxifen users, and that being hospitalized with a bone fracture was 249 
significantly associated with overall mortality. 250 
It has previously been shown that breast cancer adjuvant treatment, in particular hormonal 251 
treatment, may affect bone metabolism and bone mineral density, thus potentially influencing 252 
the risk of fractures in breast cancer patients (Becker 2012, Breast Cancer Trials Committee 253 
1987, Fisher 1989, Rutqvist 2007, Cooke 2008, Amir 2011, Edwards 2011, Santen 2011). 254 
Still, some previous observational studies were unable to show a significantly increased risk 255 
of bone fracture in women with a previous breast cancer (Melton 2012, Pawloski 2013). An 256 
increased risk of bone fractures as compared with the general population was nonetheless 257 
found in other hormone-dependent tumors (Melton 2011, Thorstenson 2012). In our study we 258 
found a significant long-term increase (up to 10 years) of the risk of hospitalization due to 259 
bone fracture in women with a previous breast cancer diagnosis, independent of age. This risk 260 
gradually decreased during the follow-up, suggesting a potential association with treatment. 261 
The magnitude of this risk increase is however not particularly pronounced (20-25%) and 262 
may not be considered of primary clinical relevance in a breast cancer patient; however it is 263 
still an important risk estimation, and its potential impact on quality of life of women 264 
surviving with a previous breast cancer diagnosis should not be underestimated.  265 
In our study, tumor characteristics were not associated with the risk of being hospitalized 266 
with a bone fracture after a breast cancer diagnosis. In our study comorbidities were 267 
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significantly associated with the risk of being hospitalized with a bone fracture  at a Charlson 268 
comorbidity Index score of 1 (Table 2). In particular, women with at least one comorbidity 269 
and aged 60 years or less at breast cancer diagnosis showed a 10 years’ cumulative incidence 270 
of bone fracture hospitalization similar to women aged more than 60 and without 271 
comorbidities (Figure 2). 272 
Aromatase inhibitors, in combination with menopause and older age, can lead to bone loss 273 
and to a higher risk of fractures (Becker 2012, Santen 2011, Chen 2009). On the other hand, 274 
tamoxifen was shown to be protective against the risk of osteoporosis and subsequent bone 275 
fractures in postmenopausal patients (Cooke 2008, Santen 2011). Increased risk of bone 276 
fractures in breast cancer patients treated with aromatase inhibitors as compared to patients 277 
treated with tamoxifen was seen in large clinical trials (Cuzick 2010, Van Poznak 2010, 278 
Crivellari 2008). In our analysis, which is based on an observational study design, we also 279 
found an increased risk of bone fracture in patients treated with aromatase inhibitors as 280 
compared to tamoxifen treated patients (Figure 3). Bisphosphonates, a class of drugs 281 
commonly administered to prevent bone loss and treat osteoporosis, have been widely used to 282 
prevent disease recurrence and mortality in breast cancer metastatic patients (Wong 2012, 283 
van Poznak 2011, Hillner 2003). Recently, a growing body of evidence is also supporting 284 
their use in women with early breast cancer to improve prognosis (Coleman 2013, He 2013, 285 
Gnant 2009, EBCTCG 2015). Also, the use of adjuvant denosumab has been found to reduce 286 
the risk of bone fractures in postmenopausal women treated with aromatase inhibitors (Gnant 287 
2015). 288 
Bone fracture hospitalizations in individuals older than 60 years is associated with an 289 
approximately two-fold increased risk of death in the first 5 years that can remain 290 
significantly elevated up to 10 years depending on type of fracture (Bliuc 2009). Hip 291 
fractures in particular are also associated with potentially severe complications like deep vein 292 
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thrombosis, pressure ulcers and pulmonary embolism, while vertebral fractures can affect 293 
pulmonary function (Schlaich 1998, Margolis 2003, Nakase 2009, Anand 2007). Our findings 294 
showed an increased overall mortality in breast cancer patients following hospitalization with 295 
bone fracture, which was interestingly independent of other comorbidities and tumor 296 
characteristics (Table 3).  297 
In this study we used large population data sources with long and complete periods of follow-298 
up. It could be that some of the reported events were pathological fractures due to breast 299 
cancer metastasis, in case bone metastases were not correctly and timely reported to the 300 
register. However, in order to avoid this bias in the regional cohort analysis we censored at 301 
time of first distant metastasis; moreover, the lack of association between hospitalization due 302 
to bone fracture and risk of breast cancer-specific death argues against this bias being 303 
pronounced. We used specific and appropriate ICD codes to retrieve data on hospitalizations 304 
due to bone fracture from the Swedish Inpatients Register, yet we cannot rule out some 305 
degree of inaccuracy in the reporting into the register. Hip fractures usually require 306 
hospitalization, therefore we believe that our analysis captured most such cases; however 307 
there may be some underestimation in the number of other fractures associated with bone 308 
loss, like wrist or vertebral fractures, which can also be treated in an outpatients setting. We 309 
believe that many of the bone fractures in our study were related to bone loss given that the 310 
majority of the women were in postmenopausal age, and given that we could not find 311 
significant differences in the findings concerning hospitalization due to any-bone fracture and 312 
due to hip fracture, with the latter being often associated with bone loss. However, one cannot 313 
rule out the presence of a certain proportion of bone fractures in absence of bone loss (e.g., 314 
frailty that was not captured by the Charlson comorbidity index). Attribution of specific 315 
causes of death can sometimes be inaccurate, therefore the lack association we found, 316 
between hospitalization due to bone fracture and death due to breast cancer, should be taken 317 
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with caution. Finally, in this observational study, because of the study design, we could not 318 
account for other risk factors of bone fracture, such as bone mineral density at breast cancer 319 
diagnosis, use of certain medications (e.g., corticosteroids), life-style, and frailty resulting 320 
from cancer and/or treatment, and for bone preserving treatment (though bisphosphonates 321 
were gradually introduced in Sweden late into the study period) (Van Hemelrijck 2013, 322 
Søgaard 2013, Kiderlen 2014), and this may have potentially biased some of our findings.  323 
In conclusion, in our cohort women with breast cancer are at increased risk of developing 324 
bone fractures. This association is particularly pronounced in fragile patients, defined as those 325 
with one or more comorbidity, including patients ≤60 years at diagnosis. In this observational 326 
study, aromatase inhibitors-treated patients were at increased risk of being hospitalized with a 327 
bone fracture compared with tamoxifen-treated patients. Finally, hospitalization due to a bone 328 
fracture was associated with an increased risk of death.   329 
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# First hospitalization due to any bone fracture after breast cancer diagnosis 
¤ First hospitalization due to hip fracture after breast cancer diagnosis (hospitalizations for other bone fractures 
may have occurred earlier) 
§ Adjuvant treatment combinations - CT any without HT: any combination with or without radiation therapy 
including chemotherapy and not including hormone therapy; HT any without CT: any combination with or 
without radiation therapy including hormone therapy and not including chemotherapy; HT+CT any: any 
combination with or without radiation therapy including both chemotherapy and hormone therapy; other: any 
combination with or without radiation therapy not including chemotherapy or hormone therapy
Table 1. First hospitalization due to bone fracture within 10 years after breast cancer diagnosis in women 
from the Stockholm Breast Cancer Register’s regional cohort, Stockholm-Gotland counties, 1990-2006. 
 Any bone  
fracture
#
 (%) 
No bone 
fracture (%) 
Hip 
fracture
¤
 (%) 
No hip 
fracture (%) 
Total (%) 
Age      
≤ 50 years 77 (12.8) 3701 (30.2) 12 (5.7) 3766 (29.8) 3778 (29.4) 
51-60 years 139 (23.2) 4052 (33.1) 31 (14.8) 4160 (32.9) 4191 (32.6) 
61-74 years 384 (64.0) 4497 (36.7) 166 (79.4) 4715 (37.3) 4881 (38.00) 
Period      
1990-1994 260 (43.3) 3136 (25.6) 102 (48.8) 3294 (26.1) 3396 (26.4) 
1995-1999 222 (37.0) 3381 (27.6) 75 (35.9) 3528 (27.9) 3603 (28.0) 
2000-2006 118 (19.7) 5733 (46.8) 32 (15.3) 5819 (46.0) 5851 (45.5) 
Tumor size      
More than 20mm 171 (28.50) 3427 (27.98) 62 (29.7) 3536 (28.0) 3598 (28.0) 
Less than 20mm 413 (68.83) 8631 (70.46) 140 (67.0) 8904 (70.4) 9044 (70.4) 
Missing 16 (2.67) 192 (1.57) 7 (3.4) 201 (1.6) 208 (1.6) 
Lymph node status      
Positive nodes 176 (29.3) 4045 (33.0) 63 (30.1) 4158 (32.9) 4221 (32.9) 
Negative nodes 389 (64.8) 7558 (61.7) 129 (61.7) 7818 (61.9) 7947 (61.8) 
Missing 35 (5.8) 647 (5.3) 17 (8.1) 665 (5.3) 682 (5.3) 
ER-status      
ER-positive 392 (65.3) 8082 (66.0) 150 (71.8) 8324 (65.9) 8474 (66.0) 
ER-negative 82 (13.7) 1790 (14.6) 25 (12.0) 1847 (14.6) 1872 (14.6) 
Missing 126 (21.0) 2378 (19.4) 34 (16.3) 2470 (19.5) 2504 (19.5) 
Charlson 
Comorbidity Index 
     
0 372 (62.0) 10,264 (83.8) 106 (50.7) 10,530 (83.3) 10,636 (82.8) 
1 145 (24.2) 1,467 (12.0) 65 (31.1) 1,547 (12.2) 1,612 (12.5) 
2 or more 83 (13.8) 484 (4.0) 38 (18.2) 529 (4.2) 567 (4.4) 
Missing 0 (0.0) 35 (0.3) 0 (0.0) 35 (0.3) 35 (0.0) 
Adjuvant 
treatment
§ 
     
CT any without 
HT 
35 (5.8) 1369 (11.2) 5 (2.4) 1399 (11.1) 1404 (10.9) 
HT any without 
CT 
403 (67.2) 6943 (56.7) 151 (72.3) 7195 (56.9) 7346 (57.2) 
HT+CT any 51 (8.5) 2224 (18.2) 11 (5.3) 2264 (17.9) 2275 (17.7) 
Other 111 (18.5) 1714 (14.0) 42 (20.1) 1783 (14.1) 1825 (14.2) 
Type of surgery      
Total mastectomy 292 (48.7) 4820 (39.4) 113 (54.1) 4999 (40.0) 5112 (39.8) 
Partial 
mastectomy 
298 (49.7) 7246 (59.2) 95 (45.5) 7449 (58.9) 7544 (58.7) 
Other 10 (1.7) 174 (1.4) 1 (0.5) 183 (1.5) 184 (1.4) 
Missing 0 (0.0) 10 (0.1) 0 (0.0) 10 (0.1) 10 (0.1) 
Total 600 (100.0) 12250 (100.0) 209 (100.0) 12641 (100.0) 12850 (100.0) 
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# All estimates are adjusted for all variables shown in the table  
* Statistically significant at alfa=0.05 
§ Adjuvant treatment combinations - CT any without HT: any combination with or without radiation 
therapy including chemotherapy and not including hormone therapy; HT any without CT: any 
combination with or without radiation therapy including hormone therapy and not including 
chemotherapy; HT+CT any: any combination with or without radiation therapy including both 
chemotherapy and hormone therapy; other: any combination with or without radiation therapy not 
including chemotherapy or hormone therapy 
  
Table 2. Adjusted hazard ratios# for first hospitalization due to bone fracture within 10 years since breast 
cancer diagnosis in women from the Stockholm Breast Cancer Register’s regional cohort, Stockholm-
Gotland counties, 1990-2006. 
 Any bone fracture 
HR (95% CI) 
Hip fracture 
HR (95% CI) 
Age   
<50 years 0.28 (0.20-0.38)* 0.10 (0.05-0.22)* 
51-60 years 0.42 (0.33-0.53)* 0.24 (0.15-0.39)* 
61-74 years 1.0 (ref.) 1.0 (ref.) 
Calendar period   
1990-1994 0.91 (0.73-1.13) 1.03 (0.72-1.47) 
1995-1999 1.0 (ref.) 1.0 (ref.) 
2000-2006 0.91 (0.69-1.21) 0.96 (0.57-1.61) 
Tumor characteristics   
Tumor size larger than 20mm 1.21 (0.98-1.50) 1.26 (0.89-1.78) 
Tumor size smaller than 20mm 1.0 (ref.) 1.0 (ref.) 
Positive lymph nodes 1.00 (0.80-1.25) 1.26 (0.89-1.79) 
Negative lymph nodes 1.0 (ref.) 1.0 (ref.) 
ER-positive 1.0 (ref.) 1.0 (ref.) 
ER-negative 1.14 (0.85-1.53) 0.90 (0.54-1.51) 
Charlson Comorbidity Index    
0 1.0 1.0 
1 1.63 (1.29-2.06)* 2.31 (1.61-3.32)* 
2 or more 2.44 (1.85-3.24)* 3.01 (1.95-4.64)* 
Adjuvant treatment combination
§ 
  
CT any combination without HT 0.98 (0.68-1.40) 0.41 (0.12-1.37) 
HT any combination without CT 1.0 (ref.) 1.0 (ref.) 
HT and CT any combination 0.98 (0.63-1.50) 0.97 (0.47-1.97) 
Other 1.04 (0.70-1.54) 1.01 (0.65-1.57) 
Surgery   
Total mastectomy 1.0 (ref.) 1.0 (ref.) 
Partial mastectomy 0.80 (0.65-0.98)* 0.65 (0.46-0.92)* 
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Table 3. Adjusted§ hazard ratios (95%CI) for all-cause, breast cancer and other-cause of 
death comparing breast cancer patients with and without a hospitalization due to a bone 
fracture, Stockholm Breast Cancer Register’s regional cohort, Stockholm-Gotland counties, 
1990-2006. 
Causes of death HR (95% CI) 
Overall death 1.83 (1.50-2.22)* 
Breast cancer-specific death 0.96 (0.66-1.40) 
Other cause of death 2.78 (2.11-3.67)* 
 
§ Model adjusted for age at diagnosis, calendar period, lymph node positivity, ER-status, tumor size, 
Charlson comorbidity Index, adjuvant treatment combination and type of surgery 
*Statistically significant at alfa=0.05
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Figure legends 
Figure 1. Rate ratios for hospitalization due to bone fracture after breast cancer diagnosis by 
time since diagnosis and by attained age, Swedish national cohort, 1990-2010. 
Figure 2. Risk of first hospitalization due to bone fracture after breast cancer diagnosis by 
age and Charlson comorbity index (CCI) in women from the SBCR regional cohort, 
Stockholm-Gotland counties, 1990-2006. 
Figure 3. Risk of first hospitalization due to bone fracture by tamoxifen/aromatase inhibitors 
after breast cancer diagnosis in women from the SBCR regional cohort, Stockholm-Gotland 
counties, 2005-2008, with additional merge to the Swedish Prescribed Drug Register and 
follow-up until 2013
#
. 
Footnote: # Premenopausal women, women diagnosed with distant metastases, women aged>75 years 
at diagnosis, and women with a bone fracture history before breast cancer diagnosis were excluded 
from this analysis. 
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Title: Table 1 supplementary - Description of data: Site distribution of first hospitalizations 
due to bone fracture since breast cancer diagnosis, according to age and time since diagnosis, 
Swedish national cohort, 1990-2010. 



Table 1 supplementary. Site distribution of first hospitalizations due to bone fracture since breast cancer diagnosis, according to age and time since 
diagnosis, Swedish national cohort, 1990-2010. 
 Diagnosed with breast cancer (aged<75 years at diagnosis) 
Not diagnosed with 
breast cancer 
Site of bone 
fracture  
Total Age at diagnosis (years) Time since diagnosis (years) Age 45-84 years at 
hospitalisation   <=50  51-60 61-74 0-2 2-5 5+ 
N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) 
Column  612 (5.6) 68 (5.5) 112 (4.9) 432 (5.9) 96 (6.4) 133 (5.6) 383 (5.5) 46,363 (5.9) 
Chest  304 (2.8) 42 (3.4) 72 (3.2) 190 (2.6) 42 (2.8) 64 (2.7) 198 (2.8) 20,448 (2.6) 
Pelvis  652 (6.0) 40 (3.3) 102 (4.5) 510 (6.9) 57 (3.8) 120 (5.0) 475 (6.8) 49,637 (6.3) 
Upper limb  2,475 (22.8) 330 (26.9) 631 (27.7) 1,514 (20.6) 365 (24.3) 574 (24.0) 1,536 (22.0) 160,634 (20.4) 
Hip  4,008 (36.9) 187 (15.2) 600 (26.4) 3,221 (43.7) 446 (29.7) 754 (31.5) 2,808 (40.3) 325,745 (41.4) 
Lower limb 
(excluding hip)  
2,556 (23.5) 551 (44.9) 713 (31.4) 1,292 (17.5) 473 (31.4) 702 (29.4) 1,381 (19.8) 166,954 (21.2) 
Multiple, other 
or unspecified 
259 (2.4) 10 (0.8) 44 (1.9) 205 (2.8) 25 (1.7) 44 (1.8) 190 (2.7) 17,092 (2.2) 
All 10,866 (100.0) 1,228 (100.0) 2,274 (100.0) 7,364 (100.0) 1,504 (100.0) 2,391 (100.0) 6,971 (100.0) 786,873 (100.0) 
 
  
